|Part of a series of articles on|
Silver nanoparticles are nanoparticles of silver of between 1 nm and 100 nm in size. While frequently described as being 'silver' some are composed of a large percentage of silver oxide due to their large ratio of surface-to-bulk silver atoms. Numerous shapes of nanoparticles can be constructed depending on the application at hand. Commonly used are spherical silver nanoparticles but diamond, octagonal and thin sheets are also popular.
Silver nanoparticles may eventually offer treatment of various diseases[medical citation needed]. However, a thesis from Uppsala university in 2015 showed that the use of silver nanoparticles is a cause of antimicrobial resistance. The same thesis show that silver nanoparticles lack any effect againast bacteria.
Their extremely large surface area permits the coordination of a vast number of ligands. The properties of silver nanoparticles applicable to human treatments are under investigation in laboratory and animal studies, assessing potential efficacy, toxicity, and costs.
- 1 Synthesis
- 1.1 Methods
- 1.1.1 Wet chemistry
- 1.1.2 Ion implantation
- 1.1.3 Biogenic synthesis
- 1.2 Products and functionalization
- 1.1 Methods
- 2 Use
- 3 Safety
- 4 References
Silver nanoparticles can be synthesized by several methods. They can be divided into three broad categories: wet chemistry, ion implantation, or biogenic synthesis.
Several wet chemical methods have been developed to form silver nanoparticles. Each of these methods use the same basic mechanism: a silver ion complex is reduced to colloidal silver in the presence of a capping agent, which stabilizes the energy of the surface of the newly formed nanoparticle. These methods include citrate reduction, reduction via sodium borohydride, the silver mirror reaction, the polyol process, seed-mediated growth, and light-mediated growth. Each of these methods, or combination of methods, will offer differing degrees of control over the size distribution as well as distributions of geometric arrangements of the nanoparticle.
An early, and very common, method for synthesizing silver nanoparticles is citrate reduction. Citrate reduction involves the reduction of silver nitrate, AgNO3, to colloidal silver using trisodium citrate, Na3C6H5O7 at elevated temperature (~100 °C). In this synthesis, the citrate ion acts as both the reducing and capping agent. This method is useful due to its relative ease and short reaction time. However, the silver particles formed may exhibit broad size distributions and/or form several different particle geometries simultaneously.
Reduction via sodium borohydride
A similar method is the reduction of silver nitrate using sodium borohydride, NaBH4. Sodium borohydride is a stronger reducing agent than citrate, but it is not thought to participate in surface stabilization. Thus, a separate capping molecule must be used in addition to the sodium borohydride. Examples of stabilizers used include citrate, poly(vinyl pyrrolidone) (PVP), bovine serum albumin, and cetyltrimethylammonium bromide (CTAB).
The polyol process is a particularly useful method because it yields a high degree of control over both the size and geometry of the resulting nanoparticles. In general, the polyol synthesis begins with the heating of a polyol compound such as ethylene glycol, 1,5-pentanediol, or 1,2-propylene glycol7. An Ag+ species and a capping agent are added (although the polyol itself is also often the capping agent). The Ag+ species is then reduced by the polyol to colloidal nanoparticles. The polyol process is highly sensitive to reaction conditions such as temperature, chemical environment, and concentration of substrates.(add refs again here) Therefore, by changing these variables, various sizes and geometries can be selected for such as quasi-spheres, pyramids, spheres, and wires. Further study has examined the mechanism for this process as well as resulting geometries under various reaction conditions in greater detail.
Seed-mediated growth is the process in which seed nanoparticles, formed from a reduction of Ag+ to colloidal silver by any method, are placed in a growth solution. The growth solution contains an additional silver species that deposits more silver atoms onto the original seeds. Several experimental factors are manipulated to achieve size and geometry control in this method such as concentration of the substrates and the capping agent used. Parameters controlling the size and geometry of the particles is described in greater detail in various studies.
Silver mirror reaction
The silver mirror reaction involves the conversion of silver nitrate to Ag(NH3)OH. Ag(NH3)OH is subsequently reduced into colloidal silver using an aldehyde containing molecule such as a sugar. The silver mirror reaction is as follows:
- 2(Ag(NH3)2)+ + RCHO + 2OH- → RCOOH + 2Ag + 4NH3
The size and shape of the nanoparticles produced are difficult to control and often have wide distributions. However, this method is often used to apply thin coatings of silver particles onto surfaces and further study into producing more uniformly sized nanoparticles is being done.
Ion implantation has been used to create silver nanoparticles embedded in glass, polyurethane, silicone, polyethylene, and poly(methyl methacrylate). Particles are embedded in the substrate by means of bombardment at high accelerating voltages. At a fixed current density of the ion beam up to a certain value, the size of the embedded silver nanoparticles has been found to be monodisperse within the population, after which only an increase in the ion concentration is observed. A further increase in the ion beam dose has been found to reduce both the nanoparticle size and density in the target substrate, whereas an ion beam operating at a high accelerating voltage with a gradually increasing current density has been found to result in a gradual increase in the nanoparticle size. There are a few competing mechanisms which may result in the decrease in nanoparticle size; destruction of NPs upon collision, sputtering of the sample surface, particle fusion upon heating and dissociation.
The formation of embedded nanoparticles is complex, and all of the controlling parameters and factors have not yet been investigated. Computer simulation is still difficult as it involves processes of diffusion and clustering, however it can be broken down into a few different sub-processes such as implantation, diffusion, and growth. Upon implantation, silver ions will reach different depths within the substrate which approaches a Gaussian distribution with the mean centered at X depth. High temperature conditions during the initial stages of implantation will increase the impurity diffusion in the substrate and as a result limit the impinging ion saturation, which is required for nanoparticle nucleation. Both the implant temperature and ion beam current density are crucial to control in order to obtain a monodisperse nanoparticle size and depth distribution. A low current density may be used to counter the thermal agitation from the ion beam and a buildup of surface charge. After implantation on the surface, the beam currents may be raised as the surface conductivity will increase. The rate at which impurities diffuse drops quickly after the formation of the nanoparticles, which act as a mobile ion trap. This suggests that the beginning of the implantation process is critical for control of the spacing and depth of the resulting nanoparticles, as well as control of the substrate temperature and ion beam density. The presence and nature of these particles can be analyzed using numerous spectroscopy and microscopy instruments. Nanoparticles synthesized in the substrate exhibit surface plasmon resonances as evidenced by characteristic absorption bands; these features undergo spectral shifts depending on the nanoparticle size and surface asperities, however the optical properties also strongly depend on the substrate material of the composite.
The biological synthesis of nanoparticles has provided a means for improved techniques compared to the traditional methods that call for the use of harmful reducing agents like sodium borohydride. Many of these methods could improve their environmental footprint by replacing these relatively strong reducing agents. The problems with the chemical production of silver nanoparticles is usually involves high cost and the longevity of the particles is short lived due to aggregation. The harshness of standard chemical methods has sparked the use of using biological organisms to reduce silver ions in solution into colloidal nanoparticles.
In addition, precise control over shape and size is vital during nanoparticle synthesis since the NPs therapeutic properties are intimately dependent on such factors. Hence, the primary focus of research in biogenic synthesis is in developing methods that consistently reproduce NPs with precise properties.
Use of fungi and bacteria
Bacterial and fungal synthesis of nanoparticles is practical because bacteria and fungi are easy to handle and can be modified genetically with ease. This provides a means to develop biomolecules that can synthesize AgNPs of varying shapes and sizes in high yield, which is at the forefront of current challenges in nanoparticle synthesis. Fungal strains such as Verticillium and bacterial strains such as K. pneumoniae can be used in the synthesis of silver nanoparticles. When the fungus/bacteria is added to solution, protein biomass is released into the solution. Electron donating residues such as tryptophan and tyrosine reduce silver ions in solution contributed by silver nitrate. These methods have been found to effectively create stable monodisperse nanoparticles without the use of harmful reducing agents.
A method has been found of reducing silver ions by the introduction of the fungus Fusarium oxysporum. The nanoparticles formed in this method have a size range between 5 and 15 nm and consist of silver hydrosol. The reduction of the silver nanoparticles is thought to come from an enzymatic process and silver nanoparticles produced are extremely stable due to interactions with proteins that are excreted by the fungi.2
Bacterium found in silver mines, Pseudomonas stutzeri AG259, were able to construct silver particles in the shapes of triangles and hexagons. The size of these nanoparticles had a large range in size and some of them reached sizes larger than the usual nanoscale with a size of 200 nm. The silver nanoparticles were found in the organic matrix of the bacteria.
Lactic acid producing bacteria have been used to produce silver nanoparticles. The bacteria Lactobacillus spp., Pediococcus pentosaceus, Enteroccus faeciumI, and Lactococcus garvieae have been found to be able to reduce silver ions into silver nanoparticles. The production of the nanoparticles takes place in the cell from the interactions between the silver ions and the organic compounds of the cell. It was found that the bacterium Lactobacillus fermentum created the smallest silver nanoparticles with an average size of 11.2 nm. It was also found that this bacterium produced the nanoparticles with the smallest size distribution and the nanoparticles were found mostly on the outside of the cells. It was also found that there was an increase in the pH increased the rate of which the nanoparticles were produced and the amount of particles produced.
Use of plants
The reduction of silver ions into silver nanoparticles has also been achieved using geranium leaves. It has been found that adding geranium leaf extract to silver nitrate solutions causes there silver ions to be quickly reduced and that the nanoparticles produced are particularly stable. The silver nanoparticles produced in solution had a size range between 16 and 40 nm.
In another study different plant leaf extracts were used to reduce silver ions. It was found that out of pine, persimmon, ginko, magnolia, and platanus that the magnolia leaf extract was the best at creating silver nanoparticles. This method created particles with a disperse size range of 15 to 500 nm, but it was also found that the particle size could be controlled by varying the reaction temperature. The speed at which the ions were reduced by the magnolia leaf extract was comparable to those of using chemicals to reduce.
The use of plants, microbes, and fungi in the production of silver nanoparticles is leading the way to more environmentally sound production of silver nanoparticles.
Products and functionalization
Synthetic protocols for silver nanoparticle production can be modified to produce silver nanoparticles with non-spherical geometries and also to functionalize nanoparticles with different materials, such as silica. Creating silver nanoparticles of different shapes and surface coatings allows for greater control over their size-specific properties.
Silver nanoparticles can be synthesized in a variety of non-spherical (anisotropic) shapes. Because silver, like other noble metals, exhibits a size and shape dependent optical effect known as localized surface plasmon resonance (LSPR) at the nanoscale, the ability to synthesize Ag nanoparticles in different shapes vastly increases the ability to tune their optical behavior. For example, the wavelength at which LSPR occurs for a nanoparticle of one morphology (e.g. a sphere) will be different if that sphere is changed into a different shape. This shape dependence allows a silver nanoparticle to experience optical enhancement at a range of different wavelengths, even by keeping the size relatively constant, just by changing its shape. The applications of this shape-exploited expansion of optical behavior range from developing more sensitive biosensors to increasing the longevity of textiles.
Triangular shaped nanoparticles are a canonical type of anisotropic morphology studied for both gold and silver.
Though many different techniques for silver nanoprism synthesis exist, several methods employ a seed-mediated approach, which involves first synthesizing small (3-5 nm diameter) silver nanoparticles that offer a template for shape-directed growth into triangular nanostructures.
The silver seeds are synthesized by mixing silver nitrate and sodium citrate in aqueous solution and then rapidly adding sodium borohydride. Additional silver nitrate is added to the seed solution at low temperature, and the prisms are grown by slowly reducing the excess silver nitrate using ascorbic acid.
With the seed-mediated approach to silver nanoprism synthesis, selectivity of one shape over another can in part be controlled by the capping ligand. Using essentially the same procedure above but changing citrate to poly (vinyl pyrrolidone) (PVP) yields cube and rod-shaped nanostructures instead of triangular nanoprisms.
In addition to the seed mediated technique, silver nanoprisms can also be synthesized using a photo-mediated approach, in which preexisting spherical silver nanoparticles are transformed into triangular nanoprisms simply by exposing the reaction mixture to high intensities of light.
Silver nanocubes can be synthesized using ethylene glycol as a reducing agent and PVP as a capping agent, in a polyol synthesis reaction (vide supra). A typical synthesis using these reagents involves adding fresh silver nitrate and PVP to a solution of ethylene glycol heated at 140 °C. This procedure can actually be modified to produce another anisotropic silver nanostructure, nanowires, by just allowing the silver nitrate solution to age before using it in the synthesis. By allowing the silver nitrate solution to age, the initial nanostructure formed during the synthesis is slightly different than that obtained with fresh silver nitrate, which influences the growth process, and therefore, the morphology of the final product.
Coating with silica
In this method, polyvinylpyrrolidone (PVP) is dissolved in water by sonication and mixed with silver colloid particles. Active stirring ensures the PVP has adsorbed to the nanoparticle surface. Centrifuging separates the PVP coated nanoparticles which are then transferred to a solution of ethanol to be centrifuged further and placed in a solution of ammonia, ethanol and Si(OEt4) (TES). Stirring for twelve hours results in the silica shell being formed consisting of a surrounding layer of silicon oxide with an ether linkage available to add functionality. Varying the amount of TES allows for different thicknesses of shells formed. This technique is popular due to the ability to add a variety of functionality to the exposed silica surface.
Silver nanoparticles have long been known for their antibacterial, antifungal, anti-viral and anti-inflammatory properties.[medical citation needed] Recently, researchers have extend their use into chemotherapy as a device for delivering various payloads such as small drug molecules or large biomolecules to specific targets. Once the AgNP has had sufficient time to reach its target, release of the payload could be triggered by internal or external stimulus. The targeting and accumulation of nanoparticles to a designated area ensures high drug concentration at specific sites and thus minimizes side effects.
The introduction of nanotechnology into medicine is expected to advance diagnostic cancer imaging and the standards for therapeutic drug design. Nanotechnology may uncover insight about the structure, function and organizational level of the biosystem at the nanoscale.
Silver nanoparticles can undergo coating techniques that offer a uniform functionalized surface to which substrates can be added. When the nanoparticle is coated, for example, in silica the surface exists as silicic acid. Substrates can thus be added through stable ether and ester linkages that are not degraded immediately by natural metabolic enzymes. Recent chemotherapeutic applications have designed anti cancer drugs with a photo cleavable linker, such as an ortho-nitrobenzyl bridge, attaching it to the substrate on the nanoparticle surface. The low toxicity nanoparticle complex can remain viable under metabolic attack for the time necessary to be distributed throughout the bodies systems. If a cancerous tumor is being targeted for treatment, ultraviolet light can be introduced over the tumor region. The electromagnetic energy of the light causes the photo responsive linker to break between the drug and the nanoparticle substrate. The drug is now cleaved and released in an unaltered active form to act on the cancerous tumor cells. Advantages anticipated for this method is that the drug is transported without highly toxic compounds, the drug is released without harmful radiation or relying on a specific chemical reaction to occur and the drug can be selectively released at a target tissue.
A second approach is to attach a chemotherapeutic drug directly to the functionalized surface of the silver nanoparticle combined with a nucelophilic species to undergo a displacement reaction. For example, once the nanoparticle drug complex enters or is in the vicinity of the target tissue or cells, a glutathione monoester can be administered to the site. The nucleophilic ester oxygen will attach to the functionalized surface of the nanoparticle through a new ester linkage while the drug is released to its surroundings. The drug is now active and can exert its biological function on the cells immediate to its surroundings limiting non-desirable interactions with other tissues.
Multiple drug resistance
Nanoparticles can provide a means to overcome MDR. In general, when using a targeting agent to deliver nanocarriers to cancer cells, it is imperative that the agent binds with high selectivity to molecules that are uniquely expressed on the cell surface. Hence NPs can be designed with proteins that specifically detect drug resistant cells with overexpressed transporter proteins on their surface. A pitfall of the commonly used nano-drug delivery systems is that free drugs that are released from the nanocarriers into the cytosol get exposed to the MDR transporters once again, and are exported. To solve this, 8 nm nano crystalline silver particles were modified by the addition of trans-activating transcriptional activator (TAT), derived from the HIV-1 virus, which acts as a cell penetrating peptide (CPP). Generally, AgNP effectiveness is limited due to the lack of efficient cellular uptake; however, CPP-modification has become one of the most efficient methods for improving intracellular delivery of nanoparticles. Once ingested, the export of the AgNP is prevented based on a size exclusion. The concept is simple: the nanoparticles are too large to be effluxed by the MDR transporters, because the efflux function is strictly subjected to the size of its substrates, which is generally limited to a range of 300-2000 Da. Thereby the nanoparticulates remain insusceptible to the efflux, providing a means to accumulate in high concentrations.
Introduction of silver into bacterial cells induces a high degree of structural and morphological changes, which can lead to cell death. As the silver nano particles come in contact with the bacteria, they adhere to the cell wall and cell membrane. Once bound, some of the silver passes through to the inside, and interacts with phosphate-containing compounds like DNA and RNA, while another portion adheres to the sulphur-containing proteins on the membrane. The silver-sulphur interactions at the membrane cause the cell wall to undergo structural changes, like the formation of pits and pores. Through these pores, cellular components are released into the extracellular fluid, simply due to the osmotic difference. Within the cell, the integration of silver creates a low molecular weight region where the DNA then condenses. Having DNA in a condensed state inhibits the cell’s replication proteins contact with the DNA. Thus the introduction of silver nanoparticles inhibits replication and is sufficient to cause the death of the cell. Further increasing their effect, when silver comes in contact with fluids, it tends to ionize which increases the nanoparticles bactericidal activity. This has been correlated to the suppression of enzymes and inhibited expression of proteins that relate to the cell’s ability to produce ATP.
Although it varies for every type of cell proposed, as their cell membrane composition varies greatly, It has been seen that in general, silver nano particles with an average size of 10 nm or less show electronic effects that greatly increase their bactericidal activity. This could also be partly due to the fact that as particle size decreases, reactivity increases due to the surface area to volume ratio increasing.
It has been noted that the introduction of silver nano particles has shown to have synergistic activity with common antibiotics already used today, such as; penicillin G, ampicillin, erythromycin, clindamycin, and vancomycin against E. coli and S. aureus. In medical equipment, it has been shown that silver nano particles drastically lower the bacterial count on devices used. However, the problem arises when the procedure is over and a new one must be done. In the process of washing the instruments a large portion of the silver nano particles become less effective due to the loss of silver ions. They are more commonly used in skin grafts for burn victims as the silver nano particles embedded with the graft provide better antimicrobial activity and result in significantly less scarring of the victim. They also show promising application as water treatment method form clean potable water.
Using silver nanoparticles for catalysis has been gaining attention in recent years. Although the most common applications are for medicinal or antibacterial purposes, silver nanoparticles have been demonstrated to show catalytic redox properties for dyes, benzene, carbon monoxide, and likely other compounds.
NOTE: This paragraph is a general description of nanoparticle properties for catalysis; it is not exclusive to silver nanoparticles. The size of a nanoparticle greatly determines the properties that it exhibits due to various quantum effects. Additionally, the chemical environment of the nanoparticle plays a large role on the catalytic properties. With this in mind, it is important to note that heterogeneous catalysis takes place by adsorption of the reactant species to the catalytic substrate. When polymers, complex ligands, or surfactants are used to prevent coalescence of the nanoparticles, the catalytic ability is frequently hindered due to reduced adsorption ability. However, these compounds can also be used in such a way that the chemical environment enhances the catalytic ability.
Supported on silica spheres – reduction of dyes
Silver nanoparticles have been synthesized on a support of inert silica spheres. The support plays virtually no role in the catalytic ability and serves as a method of preventing coalescence of the silver nanoparticles in colloidal solution. Thus, the silver nanoparticles were stabilized and it was possible to demonstrate the ability of them to serve as an electron relay for the reduction of dyes by sodium borohydride. Without the silver nanoparticle catalyst, virtually no reaction occurs between sodium borohydride and the various dyes: methylene blue, eosin, and rose bengal.
Mesoporous aeorgel – selective oxidation of benzene
Silver nanoparticles supported on aerogel are advantageous due to the higher number of active sites. The highest selectivity for oxidation of benzene to phenol was observed at low weight percent of silver in the aerogel matrix (1% Ag). This better selectivity is believed to be a result of the higher monodispersity within the aerogel matrix of the 1% Ag sample. Each weight percent solution formed different sized particles with a different width of size range.
Silver alloy – synergistic oxidation of carbon monoxide
Au-Ag alloy nanoparticles have been shown to have a synergistic effect on the oxidation of carbon monoxide (CO). On its own, each pure-metal nanoparticle shows very poor catalytic activity for CO oxidation; together, the catalytic properties are greatly enhanced. It is proposed that the gold acts as a strong binding agent for the oxygen atom and the silver serves as a strong oxidizing catalyst, although the exact mechanism is still not completely understood. When synthesized in a Au/Ag ratio from 3:1 to 10:1, the alloyed nanoparticles showed complete conversion when 1% CO was fed in air at ambient temperature. Interestingly, the size of the alloyed particles did not play a big role in the catalytic ability. It is well known that gold nanoparticles only show catalytic properties for CO when they are ~3 nm in size, but alloyed particles up to 30 nm demonstrated excellent catalytic activity – catalytic activity better than that of gold nanoparticles on active support such as TiO2, Fe2O3, etc.
Plasmonic effects have been studied quite extensively. Until recently, there have not been studies investigating the oxidative catalytic enhancement of a nanostructure via excitation of its surface plasmon resonance. The defining feature for enhancing the oxidative catalytic ability has been identified as the ability to convert a beam of light into the form of energetic electrons that can be transferred to adsorbed molecules. The implication of such a feature is that photochemical reactions can be driven by low-intensity continuous light can be coupled with thermal energy.
The coupling of low-intensity continuous light and thermal energy has been performed with silver nanocubes. The important feature of silver nanostructures that are enabling for photocatalysis is their nature to create resonant surface plasmons from light in the visible range.
The addition of light enhancement enabled the particles to perform to the same degree as particles that were heated up to 40K greater. This is a profound finding when noting that a reduction in temperature of 25K can increase the catalyst lifetime by nearly tenfold, when comparing the photothermal and thermal process.
Although silver nanoparticles are widely used in a variety of commercial products, there has only recently been a major effort to study their effects on human health. There have been several studies that describe the in vitro toxicity of silver nanoparticles to a variety of different organs, including the lung, liver, skin, brain, and reproductive organs. The mechanism of the toxicity of silver nanoparticles to human cells appears to be derived from oxidative stress and inflammation that is caused by the generation of reactive oxygen species (ROS) stimulated by either the Ag NPs, Ag ions, or both. For example, Park et al. showed that exposure of a mouse peritoneal macrophage cell line (RAW267.7) to silver nanoparticles decreased the cell viability in a concentration- and time-dependent manner. They further showed that the intracellular reduced glutathionine (GSH), which is a ROS scavenger, decreased to 81.4% of the control group of silver nanoparticles at 1.6 ppm.
Modes of toxicity
Since silver nanoparticles undergo dissolution releasing silver ions, which is well-documented to have toxic effects, there have been several studies that have been conducted to determine whether the toxicity of silver nanoparticles is derived from the release of silver ions or from the nanoparticle itself. Several studies suggest that the toxicity of silver nanoparticles is attributed to their release of silver ions in cells as both silver nanoparticles and silver ions have been reported to have similar cytotoxicity. For example, In some cases it is reported that silver nanoparticles facilitate the release of toxic free silver ions in cells via a "Trojan-horse type mechanism," where the particle enters cells and is then ionized within the cell. However, there have been reports that suggest that a combination of silver nanoparticles and ions is responsible for the toxic effect of silver nanoparticles. Navarro et al. using cysteine ligands as a tool to measure the concentration of free silver in solution, determined that although initially silver ions were 18 times more likely to inhibit the photosynthesis of an algae, Chlamydomanas reinhardtii, but after 2 hours of incubation it was revealed that the algae containing silver nanoparticles were more toxic than just silver ions alone. Furthermore, there are studies that suggest that silver nanoparticles induce toxicity independent of free silver ions. For example, Asharani et al. compared phenotypic defects observed in zebrafish treated with silver nanoparticles and silver ions and determined that the phenotypic defects observed with silver nanoparticle treatment was not observed with silver ion-treated embryos, suggesting that the toxicity of silver nanoparticles are independent of silver ions.
Protein channels and nuclear membrane pores can often be in the size range of 9 nm to 10 nm in diameter. Small silver nanoparticles constructed of this size have the ability to not only pass through the membrane to interact with internal structures but also to be become lodged within the membrane. Silver nanoparticle depositions in the membrane can impact regulation of solutes, exchange of proteins and cell recognition. Exposure to silver nanoparticles has been associated with "inflammatory, oxidative, genotoxic, and cytotoxic consequences"; the silver particulates primarily accumulate in the liver. but have also been shown to be toxic in other organs including the brain. Nano-silver applied to tissue-cultured human cells leads to the formation of free radicals, raising concerns of potential health risks.
- Allergic reaction: There have been several studies conducted that show a precedence for allerginicity of silver nanoparticles.
- Argyria and staining: Ingested silver or silver compounds, including colloidal silver, can cause a condition called argyria, a discoloration of the skin and organs.In 2006, there was a case study of a 17-year-old man, who sustained burns to 30% of his body, and experienced a temporary bluish-grey hue after several days of treatment with Acticoat, a brand of wound dressing containing silver nanoparticles. Argyria is the deposition of silver in deep tissues, a condition that cannot happen on a temporary basis, raising the question of whether the cause of the man’s discoloration was argyria or even a result of the silver treatment. Silver dressings are known to cause a “transient discoloration” that dissipates in 2–14 days, but not a permanent discoloration.
- Silzone heart valve: St. Jude Medical released a mechanical heart valve with a silver coated sewing cuff (coated using ion beam-assisted deposition) in 1997. The valve was designed to reduce the instances of endocarditis. The valve was approved for sale in Canada, Europe, the United States, and most other markets around the world. In a post-commercialization study, researchers showed that the valve prevented tissue ingrowth, created paravalvular leakage, valve loosening, and in the worst cases explantation. After 3 years on the market and 36,000 implants, St. Jude discontinued and voluntarily recalled the valve.
- Graf, Christina; Vossen, Dirk L.J.; Imhof, Arnout; van Blaaderen, Alfrons (July 11, 2003). "A General Method To Coat Colloidal Particles with Silica". Langmuir. 19 (17): 6693–6700. doi:10.1021/la0347859.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Dong, X.; Ji, X.; Jing, J.; Li, M.; Li, J.; Yang, W. (2010). "Synthesis Of Triangular Silver Nanoprisms by Stepwise Reduction of Sodium Borohydride and Trisodium Citrate". J. Phys. Chem. C. 114 (5): 2070–2074. doi:10.1021/jp909964k.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Shan, Z.; Wu, J.; Xu, F.; Huang, F.-Q.; Ding, H. (2008). "Highly Effective Silver/Semiconductor Photocatalytic Composites Prepared By a Silver Mirror Reaction". J. Phys. Chem. C. 112 (39): 15423–15428. doi:10.1021/jp804482k.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Wiley, B.; Sun, Y.; Xia, Y. Synthesis Of Silver Nanostructures with Controlled Shapes and Properties. Accounts of Chemical Research Acc. Chem. Res. 2007, 40, 1067–1076.
- Pietrobon, B.; Mceachran, M.; Kitaev, V. Synthesis Of Size-Controlled Faceted Pentagonal Silver Nanorods with Tunable Plasmonic Properties and Self-Assembly of These Nanorods. ACS Nano. 2009, 3, 21–26.
- Tanimoto, H.; Ohmura, S.; Maeda, Y. Size-Selective Formation Of Hexagonal Silver Nanoprisms in Silver Citrate Solution by Monochromatic-Visible-Light Irradiation. J. Phys. Chem. C.2012, 116, 15819–15825.
- Rycenga, M.; Cobley, C. M.; Zeng, J.; Li, W.; Moran, C. H.; Zhang, Q.; Qin, D.; Xia, Y. (2011). "Controlling The Synthesis and Assembly of Silver Nanostructures for Plasmonic Applications". Chemical Reviews. 111 (6): 3669–3712. doi:10.1021/cr100275d.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Dong, X.; Ji, X.; Wu, H.; Zhao, L.; Li, J.; Yang, W. Shape Control Of Silver Nanoparticles by Stepwise Citrate Reduction. J. Phys. Chem. 2009, 113, 6573–6576.
- Pillai, Z. S.; Kamat, P. V. What Factors Control The Size and Shape of Silver Nanoparticles in the Citrate Ion Reduction Method? J. Phys. Chem. B. 2004, 108, 945–951
- Liu, L.; Wei, T.; Guan, X.; Zi, X.; He, H.; Dai, H. Size And Morphology Adjustment of PVP-Stabilized Silver and Gold Nanocrystals Synthesized by Hydrodynamic Assisted Self-Assembly. J. Phys. Chem. 2009, 113, 8595–8600.
- Tang, B.; Xu, S.; Tao, J.; Wu, Y.; Xu, W.; Ozaki, Y. Two-Dimensional Correlation Localized Surface Plasmon Resonance Spectroscopy For Analysis of the Interaction between Metal Nanoparticles and Bovine Serum Albumin. J. Phys. Chem.2010, 114, 20990–20996.
- Chakraborty, M.; Hsiao, F.-W.; Naskar, B.; Chang, C.-H.; Panda, A. K. Surfactant-Assisted Synthesis And Characterization of Stable Silver Bromide Nanoparticles in Aqueous Media" Langmuir 2012; 28, 9906–9906.
- Xia, Y.; Xiong, Y.; Lim, B.; Skrabalak, S. E. Shape-Controlled Synthesis Of Metal Nanocrystals: Simple Chemistry Meets Complex Physics?" Angew. Chem. Int. Ed 2008; 48, 60–103.
- Zhang, Q.; Li, W.; Moran, C.; Zeng, J.; Chen, J.; Wen, L.-P.; Xia, Y. Seed-Mediated Synthesis Of Ag Nanocubes with Controllable Edge Lengths in the Range of 30−200 Nm and Comparison of Their Optical Properties" J. Am. Chem. Soc 2010; 132, 11372–11378.
- Wu, X.; Redmond, P. L.; Liu, H.; Chen, Y.; Steigerwald, M.; Brus, L. Photovoltage Mechanism For Room Light Conversion of Citrate Stabilized Silver Nanocrystal Seeds to Large Nanoprisms" J. Am. Chem. Soc 2009; 130, 9500–9506.
- V. N. Popok, V. B. Odzhaev, A. L. Stepanov. "Synthesis of Silver Nanoparticles by the Ion Implantation Method and Investigation of their Optical Properties." Journal of Applied Spectroscopy. 2005. Volume 72. Number 2. Page 229.
- Stepanov, A. "Synthesis Of Silver Nanoparticles In Dielectric Matrix By Ion Implantation: A Review." Review of Advanced Material Science. 2010. Volume 26. Pages 1-29.
- Song, Jae Yong; Kim, Beom Soo (2008-04-26). "Rapid biological synthesis of silver nanoparticles using plant leaf extracts". Bioprocess and Biosystems Engineering. 32 (1): 79–84. doi:10.1007/s00449-008-0224-6. ISSN 1615-7591.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Shankar, S. Shiv; Ahmad, Absar; Sastry, Murali (2003-01-01). "Geranium Leaf Assisted Biosynthesis of Silver Nanoparticles". Biotechnology Progress. 19 (6): 1627–1631. doi:10.1021/bp034070w. ISSN 1520-6033. PMID 14656132.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Bhattacharya, Resham; Mukherjee, Priyabrata (March 12, 2008). "Biological properties of "naked" metal nanoparticles". Advanced Drug Delivery Reviews. 60 (11): 1289–306. doi:10.1016/j.addr.2008.03.013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Shankar, S Shiv; Rai, Akhilesh; Ahmad, Absar; Sastry, Murali (July 15, 2007). "Rapid synthesis of Au, Ag, and bimetallic Au core–Ag shell nanoparticles using Neem (Azadirachta indica) leaf broth". Journal of Colloid and Interface Science. 275 (2): 496–502. doi:10.1016/j.jcis.2004.03.003.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Li, Guangquan; He, Dan; Qian, Yongqing; Guan, Buyuan; Gao, Song; Cui, Yan; Yokoyama, Koji; Wang, Li (December 29, 2011). "Biological synthesis of silver nanoparticles using the fungus Aspergillus flavus". Int. J. Mol. Sci. 13 (1): 466–476. doi:10.3390/ijms13010466.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Ahmad, Absar; Mukherjee, Priyabrata; Senapati, Satyajoyti; Mandal, Deendayal; Khan, M.Islam; Kumar, Rajiv; Sastry, Murali (January 16, 2003). "Extracellular biosynthesis of silver nanoparticles using the fungus Fusarium oxysporum". Colloids and Surfaces B: Biointerfaces. 28 (4): 313–318. doi:10.1016/s0927-7765(02)00174-1.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Klaus, Tanja; Joerger, Ralph; Olsson, Eva; Granqvist, Claes-Göran (1999-11-23). "Silver-based crystalline nanoparticles, microbially fabricated". Proceedings of the National Academy of Sciences. 96 (24): 13611–13614. doi:10.1073/pnas.96.24.13611. ISSN 0027-8424. PMID 10570120.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Sintubin, Liesje; Windt, Wim De; Dick, Jan; Mast, Jan; Ha, David van der; Verstraete, Willy; Boon, Nico (2009-06-02). "Lactic acid bacteria as reducing and capping agent for the fast and efficient production of silver nanoparticles". Applied Microbiology and Biotechnology. 84 (4): 741–749. doi:10.1007/s00253-009-2032-6. ISSN 0175-7598.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Abel, B.; Coskun, S.; Mohammed, M.; Williams, R.; Unalan, H. E.; Aslan, K. "Metal-Enhanced Fluorescence from Silver Nanowires with High Aspect Ratio on Glass Slides for Biosensing Applications" J. Phys. Chem. C. 2015, 119, 675-684. doi:10.1021/jp509040f
- Tang, B.; Zhang, M.; Hou, X.; Li, J.; Sun, L.; Wang, X. "Colored and Functional Silver Nanoparticle−Wool Fiber Composites" Ind. Eng. Chem. Res. 2012, 51, 12807-12813. doi:10.1021/am101224v
- Millstone J. E., Park S., Shuford K. L., Qin L., Schatz G. C., Mirkin C. A. (2005). "Observation of a Quadrupole Plasmon Mode for a Colloidal Solution of Gold Nanoprisms". J. Am. Chem. Soc. 127: 5312–5313. doi:10.1021/ja043245a.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Dong, X.; Ji, X.; Jing, J.; Li, M.; Li, J.; Yang, W. J. Phys. Chem. C. 2010, 114, 2070-2074.
- Zeng J., Zheng Y., Rycenga M., Tao J., Li Z., Zhang Q., Zhu Y. (2010). "Controlling the Shapes of Silver Nanocrystals with Different Capping Agents". J. Am. Chem. Soc. 132: 8552–8553. doi:10.1021/ja103655f.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Xue C., Métraux G. S., Millstone J. E., Mirkin C. A. (2008). "Mechanistic study of photomediated triangular silver nanoprism growth". J. Am. Chem. Soc. 130: 8337–8344. doi:10.1021/ja8005258.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Chang, S.; Chen, K.; Hua, Q.; Ma, Y.; Huang. W. "Evidence for the growth mechanisms of silver nanocubes and nanowires" J. Phys. Chem. C. 2011, 115, 7979-7986. doi:10.1021/jp2010088
- Pickup, J.C.; Zhi, Z.L.; Khan, F.; Saxl, T.; Birch, D.J. "Birch nanomedicine and its potential in diabetes research and practice". Diabetes Metab Res Rev. 24 (8): 604–610. doi:10.1002/dmrr.893. PMID 18802934.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Peer, Dan; Karp, Jeffrey M.; Hong, Seungpyo; Farokhzad, Omid C.; Margalit, Rimona; Langer, Robert. "Nanocarriers as an emerging platform for cancer therapy". Nature Nanotechnology. 2: 751–760. Bibcode:2007NatNa...2..751P. doi:10.1038/nnano.2007.387.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Kairemo, Kalevi; Erba, Paola; Bergström, Kim; Pauwels, Ernest K.J. (January 2010). "Nanoparticles in cancer". Current Radioparmaceuticals. 1 (1): 30–36. doi:10.2174/1874471010801010030.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Agasti, Sarit S.; Chompoosor, Apiwat; You, Chang-Cheng; Ghosh, Partha; Kim, Chae Kyu; Rotello, Vincent M. (April 7, 2009). "Photoregulated release of caged anticancer drugs from gold nanoparticles". J. Am. Chem. Soc. 131 (16): 5728–5729. doi:10.1021/ja900591t.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Mukherjee, Sudip; Chowdhury, Debabrata; Kotcherlakota, Rajesh; Parta, Sujata; B, Vinothkumar; Bhadra, Manika Pal; Sreedhar, Bojja; Patra, Chitta Ranjan (January 29, 2014). "Potential theranostic application of biosynthesized silver nanoparticles". Theranostics. 4 (3): 316–335. doi:10.7150/thno.7819.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Kim, Moon Suk; Diamond, Scott L. (August 2006). "Photocleavage of o-nitrobenzyl ether derivatives for rapid biomedical release applications". Bioorganic & Medicinal Chemistry Letters. 16 (15): 4007–4010. doi:10.1016/j.bmcl.2006.05.013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- "Ions, not particles, make silver toxic to bacteria". Phys Org. Retrieved February 28, 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Hong, Rui; Han, Gang; Fernández, Joseph M.; Kim, Byoung-jin; Forbes, Neil S.; Rotello, Vincent M. (2006). "Glutathione mediated delivery and release using monolayer protected nanoparticle carriers". J. Am. Chem. Soc. 128 (4): 1078–1079. doi:10.1021/ja056726i.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Ock, Kwangsu; Jeon, Won II; Ganbold, Erdene Ochir; Kim, Mira; Park, Jihno; Seo, Ji Hyde; Cho, Keunchang; Jooo, Sang-Woo; Lee, So Yeong (January 26, 2012). "Real time monitoring of glutathione triggered thiopurine anticancer drug release in live cells investigated by surface enhanced raman scattering". Analytical Chemistry. 84 (5): 2172–2178. doi:10.1021/ac2024188.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Fodale, V.; Pierobon, M.; Liotta, L.; Petricoin, E. "Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?". Cancer J. 17 (2): 89–95. doi:10.1097/PPO.0b013e318212dd3d.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Ghosh, Partha; Han, Gang; De, Mrinmoy; Kim, Chae Kyu; Rotello, Vincent M. (August 17, 2008). "Gold nanoparticles in delivery applications". Advance Drug Delivery Reviews. 60 (11): 1307–1315. doi:10.1016/j.addr.2008.03.016.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Liu, J.; Zhao, Y.; Guo, Q.; Wang, Z.; Wang, H.; Yang, Y.; Huang, Y. (September 2012). "TAT-modified nanosilver for combating multidrug-resistant cancer". Biomaterials. 33 (26): 6155–6161. doi:10.1016/j.biomaterials.2012.05.035.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Klasen, H.J. (March 2000). "A historical review of the use of silver in the treatment of burns". Burns. 26 (2): 117–130. doi:10.1016/s0305-4179(99)00108-4.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Feng, Q.L.; Wu, J.; Chen, G.Q.; Cui, F.Z.; Kim, T.N.; Kim, J.O. (December 15, 2000). "A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus". J. Biomed. Mater. Res. 52 (4): 662–668. doi:10.1002/1097-4636(20001215)52:4<662::aid-jbm10>3.0.co;2-3.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Yamanaka, Mikihiro; Hara, Keita; Kudo, Jun (November 2005). "Bactericidal Actions of a Silver Ion Solution on Escherichia coli, Studied by Energy-Filtering Transmission Electron Microscopy and Proteomic Analysis". Applied and Environmental Microbiology. 71 (11): 7589–7593. doi:10.1128/AEM.71.11.7589-7593.2005.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Pal, Sukdeb; Tak, Yu Kyung; Song, Joon Myong (January 16, 2007). "Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli". Applied and Environmental Microbiology. 73 (6): 1712–1720. doi:10.1128/AEM.02218-06.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Shahverdi, Ahmad R.; Fakhimi, Ali; Shahverdi, Hamid Q.; Minaian, Sara (May 10, 2007). "Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli". Nanomedicine. 3 (2): 168–171. doi:10.1016/j.nano.2007.02.001. PMID 17468052.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Jain, P.; Pradeep, T. (April 5, 2005). "Potential of silver nanoparticle-coated polyurethane foam as an antibacterial water filter". Biotechnol. Bioeng. 90 (1): 59–63. doi:10.1002/bit.20368.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Jiang, Zhong-Jie; Liu, Chun-Yan; Sun, Lu-Wei (2005-02-01). "Catalytic Properties of Silver Nanoparticles Supported on Silica Spheres". The Journal of Physical Chemistry B. 109 (5): 1730–1735. doi:10.1021/jp046032g. ISSN 1520-6106.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Ameen, K. Balkis; Rajasekar, K.; Rajasekharan, T. (2007-08-15). "Silver Nanoparticles in Mesoporous Aerogel Exhibiting Selective Catalytic Oxidation of Benzene in CO2 Free Air". Catalysis Letters. 119 (3–4): 289–295. doi:10.1007/s10562-007-9233-3. ISSN 1011-372X.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Liu, Jun-Hong; Wang, Ai-Qin; Chi, Yu-Shan; Lin, Hong-Ping; Mou, Chung-Yuan (2005-01-01). "Synergistic Effect in an Au−Ag Alloy Nanocatalyst: CO Oxidation". The Journal of Physical Chemistry B. 109 (1): 40–43. doi:10.1021/jp044938g. ISSN 1520-6106.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Christopher, Phillip; Xin, Hongliang; Linic, Suljo (2011-06-01). "Visible-light-enhanced catalytic oxidation reactions on plasmonic silver nanostructures". Nature Chemistry. 3 (6): 467–472. doi:10.1038/nchem.1032. ISSN 1755-4330.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Samsung's Silver Nano Washer Ads Reportedly Exaggerated, Nov 21, 2005
- Ahamed M, Alsalhi MS, Siddiqui MK, Alsalhi, Siddiqui (2010). "Silver nanoparticle applications and human health". Clin. Chim. Acta. 411 (23–24): 1841–1848. doi:10.1016/j.cca.2010.08.016. PMID 20719239.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Gopinath P., Gogoi S.K., Sanpuic P., Paul A., Chattopadhyay A., Ghosh S.S. (2010). "Signaling gene cascade in silver nanoparticle induced apoptosis". Colloids Surf. B. 77: 240–5. doi:10.1016/j.colsurfb.2010.01.033.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Wise JP, Goodale BC, Wise SS et al. (2010). "Silver nanospheres are cytotoxic and genotoxic to fish cells". Aquat Toxicol. 97: 34–41. doi:10.1016/j.aquatox.2009.11.016.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Foldbjerg R, Oleson P, Hougaard M, Dang DA, Hoffmann HJ, Autrup H (2009). "PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes". Toxicol Lett. 190: 156–162. doi:10.1016/j.toxlet.2009.07.009.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Park EJ, Yi J, Kim Y, Choi K, Park K (2010). "Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism". Toxicol In Vitro. 97: 34–41. doi:10.1016/j.tiv.2009.12.001.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- AshRani, P.V.; Low Kah Mun, Grace; Hande, Manoor Prakash; Valiyaveettil, Suresh (December 30, 2008). "Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells". ACS Nano. 3 (2): 279–290. doi:10.1021/nn800596w.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Kittler S., Greulich C., Diendorf J., Köller M., Epple M. (2010). "Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions". Chem. Mater. 22 (16): 4548–4554. doi:10.1021/cm100023p.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Hussain, S.M.; Hess, K.L.; Gearhart, J.M.; Geiss, K.T.; Schlager, J.J. (October 2005). "In vitro toxicity of nanoparticles in BRL 3A rat liver cells". Toxicol. In Vitro. 19 (7): 975–983. doi:10.1016/j.tiv.2005.06.034.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Miura N, Shinohara Y (2009). "Cytotoxic effect and apoptosis induction by silver nanoparticles in HeLa cells". Biochem Biophys res Commun. 390: 733–7. doi:10.1016/j.bbrc.2009.10.039.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Laban G, Nies LF, Turco RF, Bickham JW, Sepulveda MS (2009). "The effects of silver nanoparticles on fathead minnow (Pimephales promelas) embryos". Ecotoxicology. 19: 185–195. doi:10.1007/s10646-009-0404-4.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Kim S, Choi JE, Choi J et al. (2009). "Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells". Toxicol In Vitro. 23: 1076–84. doi:10.1016/j.tiv.2009.06.001.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Asharani PV, Wu YL, Gong Z, Valiyaveettil S (2008). "Toxicity of silver nanoparticles in zebrafish models". Nanotechnology. 19: 255102. doi:10.1088/0957-4484/19/25/255102.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V; Hutchison; Christensen; Peters; Hankin; Stone (April 2010). "A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity". Crit. Rev. Toxicol. 40 (4): 328–46. doi:10.3109/10408440903453074. PMID 20128631.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Ahamed M, Alsalhi MS, Siddiqui MK; Alsalhi; Siddiqui (December 2010). "Silver nanoparticle applications and human health". Clin. Chim. Acta. 411 (23–24): 1841–8. doi:10.1016/j.cca.2010.08.016. PMID 20719239.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Thiago Verano-Braga, Rona Miethling-Graff, Katarzyna Wojdyla, Adelina Rogowska-Wrzesinska, Jonathan R. Brewer, Helmut Erdmann, Frank Kjeldsen; Miethling-Graff; Wojdyla; Rogowska-Wrzesinska; Brewer; Erdmann; Kjeldsen (2014). "Insights into the Cellular Response Triggered by Silver Nanoparticles Using Quantitative Proteomics". ACS Nano. 8 (3): 2161–75. doi:10.1021/nn4050744. PMID 24512182.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Chuang; et al. "Allergenicity and toxicology of inhaled silver nanoparticles in allergen-provocation mice models". International Journal of Nanomedicine. 2013 (8): 4495–4506. doi:10.2147/IJN.S52239.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Hirai; et al. (2014). "Silver nanoparticles induce silver nanoparticle-specific allergic responses (HYP6P.274)". The Journal of Immunology. 192 (118): 19.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Trop, Marji, Michael Novak, Siegfried Rodl, Bengt Hellbom, Wolfgang Kroell, and Walter Goeseeler (2006). "Silver-coated dressing acticaot caused raised liver enzymes and argyris-like symptoms in burn patient". The Journal of Trauma, Injury, Infection and Critical Care. 60 (3): 648–652. doi:10.1097/01.ta.0000208126.22089.b6.CS1 maint: uses authors parameter (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Parkes, A. (2006). "Silver-coated dressing Acticoat". Journal of Trauma-Injury Infection & Critical Care. 61 (1): 239–40. doi:10.1097/01.ta.0000224131.40276.14.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
- Horstkotte, D.; Bergemann, R. (2001). "Thrombogenicity of the St. Jude medical prosthesis with and without silzone-coated sewing cuffs". The Annals of thoracic surgery. 71 (3): 1065. doi:10.1016/S0003-4975(00)02363-8. PMID 11269440.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>